Zc(=o)oy, Wherein Z Is An Acyclic Radical Bonded To The C=o By A Carbon And Y Is An Organic Radical Bonded To The Oxygen By A Carbon Patents (Class 514/546)
  • Patent number: 8987262
    Abstract: The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroïds, interferon or vincristine, generally used for the treatment of hemangiomas.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: March 24, 2015
    Assignees: Universite de Bordeaux, Centre Hospitalier Universitaire de Bordeaux
    Inventors: Christine Leaute-Labreze, Eric Dumas De La Roque, Alain Taieb, Jean-Benoit Thambo
  • Patent number: 8980869
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: March 17, 2015
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventor: Pedro Cuevas Sànchez
  • Patent number: 8980946
    Abstract: The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using non-daily administration of e.g., a MetAP-2 inhibitor.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: March 17, 2015
    Assignee: Zafgen, Inc.
    Inventor: Thomas E. Hughes
  • Publication number: 20150073476
    Abstract: The present invention relates to compositions comprising shape memory polymer (SMP) materials and uses thereof. Particularly, although not exclusively, the present invention relates to biocompatible shape memory polymer (SMP) materials and uses thereof in the medical field.
    Type: Application
    Filed: October 5, 2012
    Publication date: March 12, 2015
    Inventors: Malcolm Brown, Horacio Montes de Oca Balderas, Michael Andrew Hall, Alan William Bull, David Franklin Farrar, Philip Caton-Rose, Philip David Coates, Glen Thompson, Michael Martyn, Ian MacMillan Ward, Mark James Bonner, Peter John Hine, Paul Unwin, Robin Anthony Chivers, Michael Woodhead
  • Publication number: 20150073048
    Abstract: Antimicrobial compositions comprising one or more compound components generally recognized as safe for human consumption, and related methods of use, such compositions and methods as can be employed in a wide range of agricultural, industrial, building, pharmaceutical and/or personal care products and applications.
    Type: Application
    Filed: May 15, 2014
    Publication date: March 12, 2015
    Inventors: Niranjan Ramanlal Gandhi, Victoria Palmer Skebba, Gary A. Strobel
  • Publication number: 20150065571
    Abstract: Use of a ketone body and a ketone body ester for preserving glycogen and/or protein, thereby reducing muscle breakdown and improving endurance during exercise and promoting muscle recovery following exercise. Also for retarding muscle wasting in aging and disease. (R)-3-hydroxybutyl (R)-3-hydroxybutyrate for use in reducing muscle glycogen and protein breakdown during exercise or decreasing muscle wasting in aging and disease. Certain esters of hydroxybutyrate monomers, particularly a monoester of D-?-hydroxybutyrate with R-1,3-butanediol or with glycerol to reduce muscle breakdown and aid muscle recovery after exercise or retard muscle wasting. Compositions containing the ketone bodies or ketone body esters are also described.
    Type: Application
    Filed: August 7, 2014
    Publication date: March 5, 2015
    Applicant: TDELTAS LIMITED
    Inventors: Kieran Clarke, Peter Cox
  • Patent number: 8969354
    Abstract: The invention relates to Fatty Acid Fumarate Derivatives; compositions comprising an effective amount of a Fatty Acid Fumarate Derivative; and methods for treating or preventing cancer, a metabolic disorder or neurodegenerative disorder comprising the administration of an effective amount of a Fatty Acid Fumarate Derivative.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: March 3, 2015
    Assignee: Catabasis Pharmaceuticals, Inc.
    Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu
  • Publication number: 20150057346
    Abstract: Methods of maintaining intramuscular myoglobin levels, maintaining maximal aerobic capacity, and enhancing the oxidative capacity of muscle in a subject in need thereof are provided. Generally, the methods include administering an effective amount of ?-hydroxy-?-methylbutyrate to the subject. The ?-hydroxy-?-methylbutyrate may be administered as part of a nutritional composition.
    Type: Application
    Filed: August 21, 2014
    Publication date: February 26, 2015
    Applicant: ABBOTT LABORATORIES
    Inventors: BENJAMIN MEADOR, SUZETTE PEREIRA, NEILE EDENS, SUSAN GAWEL, RAJ CHANDRAN, GERARD DAVIS, MENGHUA LUO
  • Patent number: 8962686
    Abstract: An effective dose of a pharmaceutically acceptable phenylbutyrate salt such as sodium phenylbutyrate applied to human ocular tissues or through injection or other means prevents ocular hypertension and treats glaucoma in humans, leading to a new medical therapy for lowering the intraocular pressure via a mechanism different from the existing glaucoma medications. This compound can be formulated in combination with topical or other forms of steroids in prevention and treatment of steroid induced ocular hypertension and glaucoma.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: February 24, 2015
    Assignee: The Chinese University of Hong Kong
    Inventors: Dennis Shun Chiu Lam, Johnson Yiu Nam Lau, Gary Hin Fai Yam, Chi Pui Pang, Christopher Kai Shun Leung, Haoyu Chen, Srinivas Kamalakara Rao, Dorothy Shu Ping Fan
  • Publication number: 20150038582
    Abstract: Therapeutic regimes for improving visual function in a subject having a deficiency in endogenously produced 11-cis retinal comprising administering the synthetic retinal derivative as a divided dose over 2-7 days then providing a resting period of 7-28 days after which the second dose of the synthetic retinal derivative is administered. Preferred synthetic retinal derivatives are 9- or 11-cis-retinyl esters. Disorders associated with deficiency in endogenously produced 11-cis retinal include retinitis pigmentosa and Leber congenital amaurosis.
    Type: Application
    Filed: March 1, 2013
    Publication date: February 5, 2015
    Applicant: QLT INC.
    Inventor: Suzanne Cadden
  • Publication number: 20150038480
    Abstract: The invention provides methods of preventing, treating or ameliorating autoimmune diseases, such as diabetes and celiac disease, by decreasing the binding of MHC class II molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of small organic compounds. The invention also provides pharmaceutical compositions comprising the therapeutically effective small organic compounds and methods of using the same.
    Type: Application
    Filed: May 29, 2012
    Publication date: February 5, 2015
    Applicants: UNIVERSITY OF FLORIDA RESERCH FOUNDATION INCORPORTED, THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate
    Inventors: Aaron Michels, Maki Nakayama, David Ostrov
  • Publication number: 20150031651
    Abstract: The invention relates to prodrugs of vitamin K2, in particular prodrugs of MK-7 in which the diketone is converted to a monosubstituted or disubstituted ester type derivative. These compounds are shown to give MK-7 in plasma.
    Type: Application
    Filed: March 4, 2013
    Publication date: January 29, 2015
    Inventors: Mona Moller, Marcel Sandberg, Inger Reidun Aukrust
  • Patent number: 8940314
    Abstract: The invention provides a repellent to harmful flying insects which comprises as an effective ingredient at least one selected from the group consisting of glycerin fatty acid ester, sorbitan fatty acid ester, acetylated monoglyceride, organic acid monoglyceride, propylene glycol fatty acid ester, polyoxyethylene sorbitan, fatty acid, sucrose fatty acid ester, sorbitan, and soybean oil fatty acid methyl ester; a method for repelling harmful flying insects which comprises the step of applying the repellent to a plant to which the insects are harmful.
    Type: Grant
    Filed: March 7, 2007
    Date of Patent: January 27, 2015
    Assignee: Riken
    Inventor: Yutaka Arimoto
  • Publication number: 20150025077
    Abstract: This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.
    Type: Application
    Filed: February 27, 2013
    Publication date: January 22, 2015
    Applicant: COYOTE PHARMACEUTICALS, INC.
    Inventors: Hiroaki Serizawa, Ankush B. Argade, Akash Datwani, Natalie Spencer, Yonghua Pan, Florian Ermini
  • Publication number: 20150018415
    Abstract: Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions. These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.
    Type: Application
    Filed: August 22, 2014
    Publication date: January 15, 2015
    Inventor: Richard L. Veech
  • Publication number: 20150018294
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides for methods and pharmaceutical agents to modulate the activity of Tousled-like kinase (TLK). The invention also provides for methods and pharmaceutical agents to inhibit the activity of Tousled-like kinase to provide increased sensitivity to irradiation (IR) and chemotherapeutic agents. The invention also provides for methods and pharmaceutical agents to increase the activity of Tousled-like kinase to provide increased protection against DNA damaging agents including to irradiation (IR) and chemotherapeutic agents.
    Type: Application
    Filed: February 7, 2013
    Publication date: January 15, 2015
    Inventors: Arrigo DE BENEDETTI, Gulshan SUNAVALA
  • Publication number: 20150017227
    Abstract: Disclosed are methods and compositions for treating skin diseases or conditions with a composition containing a lipid component as an active ingredient.
    Type: Application
    Filed: July 11, 2014
    Publication date: January 15, 2015
    Inventors: Byung Eui Kim, Donald Y.M. Leung
  • Publication number: 20150005377
    Abstract: Provided herein, inter alia, are prodrugs of bimatoprost, methods of using the same and compositions including the same.
    Type: Application
    Filed: September 16, 2014
    Publication date: January 1, 2015
    Inventors: David F. Woodward, Jenny W. Wang, Neil J. Poloso, Todd S. Gac, Robert M. Burk, Michael E. Garst
  • Patent number: 8912231
    Abstract: A method of treating airway remodeling symptom caused by phthalate esters, by providing a medication comprising: a ginger compound selected from one of (a) [6]-shogaol, (b) [6]-shogaol and [10]-gingerol, (c) [6]-shogaol and [8]-gingerol, and (d) [6]-shogaol and [6]-gingerol, and an acceptable carrier or excipient, which can relieve the airway remodeling symptoms of asthma, particularly to phthalate ester-induced airway remodeling, by suppressing the proliferation and migration of bronchial smooth muscle cells and reducing the instances of fatal asthma.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: December 16, 2014
    Assignee: Kaohsiung Medical University
    Inventors: Ying-Chin Ko, Po-Lin Kuo
  • Patent number: 8912230
    Abstract: The invention relates to the use of a molecule selected from the group which consists of geranyl acetate, geraniol, isomenthone, limonene or a mixture of at least two of the above, for preparing a drug for treating or preventing vascular endothelial cell senescence and subjacent tissue degeneration induced by repeated inflammatory episodes. Specifically, the drug is useful for treating vascular endothelial cell senescence and tissue degeneration induced by repeated inflammatory episodes resulting from the presence of cancer cells.
    Type: Grant
    Filed: October 23, 2006
    Date of Patent: December 16, 2014
    Assignee: Aisa Therapeutics
    Inventor: Patrizia D'Alessio
  • Patent number: 8912171
    Abstract: The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compositions comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: December 16, 2014
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventor: Pedro Cuevas Sànchez
  • Publication number: 20140363395
    Abstract: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infection.
    Type: Application
    Filed: July 24, 2014
    Publication date: December 11, 2014
    Inventors: Theodore J. Nitz, Janet A. Gaboury, Christopher J. Burns, Sylvie Laquerre, Daniel C. Pevear, Thomas A. Lessen, David J. Rys
  • Publication number: 20140363523
    Abstract: The present invention provides a compound of Formula (I), wherein: each X is independently hydrogen or deuterium; and at least one X is deuterium.
    Type: Application
    Filed: January 17, 2013
    Publication date: December 11, 2014
    Inventor: Adam Morgan
  • Patent number: 8906858
    Abstract: The present invention relates to a method for the prophylactic and/or therapeutic treatment of glucocorticoid induced osteoporosis comprising maintaining or restoring AP-1 activity or AP-1-mediated effects, for example by LIF treatment. The method may additionally comprise a method for the treatment of a medical condition associated with inflammation comprising inhibition of NF-KB activity, for example by glucocorticoid (GC) treatment. The present invention therefore also relates to a method for the treatment and/or prevention of glucocorticoid induced osteoporosis comprising the administration of an effective amount of LIF to a subject, preferably in combination with GC treatment.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: December 9, 2014
    Assignee: Fritz-Lipmann-Institut E. V. Leibniz-Institut fuer Altersforschung
    Inventors: Jan Tuckermann, Alexander Rauch, Susanne Ostermay, Ulrike Baschant
  • Publication number: 20140357678
    Abstract: A pharmaceutically acceptable salt, prodrug or derivative compound of the formula I, wherein R1 is selected from H, a (C1-C5) alkyl group and a COR4 group; R2 is selected from H, a (C1-C5) alkyl group and a COR5 group; R3 is selected from H, a (C1-C5) alkyl group, a (C1-C5)-O-alkyl group, a cycloalkyl of (C5-C6) carbon atoms, an aryl group, and an aryl (C1-C5) alkyl group wherein the aryl group can be an unsubstituted aryl or substituted with one or more R6 groups and an NHCOR5 group, or the R2 and R3 groups together with N may form a piperidine, morpholine or piperazine group; R4 is selected from H and a (C1-C5)alkyl group; R5 is selected from an aryl group unsubstituted or substituted with one or more R6, linear or branched(C1-C5) alkyl or pyridyne groups and a pyridine group; R6 is selected from (C1-C5)alkyl groups, halogen and nitro.
    Type: Application
    Filed: January 10, 2013
    Publication date: December 4, 2014
    Inventors: Gerardo Burton, Javier Duran, David Martinez, Elvira Zini, Veronica Mora Munoz, Lucila Bertoncello
  • Patent number: 8900611
    Abstract: Provided are a sustained releaser of sex pheromone substances and a method for controlling insect pest by using the releaser, each enabling to control the simultaneous release of a mixture of sex pheromone substances having different chemical structures of one insect pest or a mixture of sex pheromone substances of insect pests, and each enabling to release the sex pheromone substances at a fixed rate or greater during the infestation period or periods of the respective insect pest or pests.
    Type: Grant
    Filed: September 14, 2005
    Date of Patent: December 2, 2014
    Assignee: Shin-Etsu Chemical Co., Ltd.
    Inventors: Tatsuya Hojo, Kinya Ogawa, Noboru Aiba, Takehiko Fukumoto
  • Publication number: 20140343119
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Application
    Filed: April 17, 2014
    Publication date: November 20, 2014
    Applicant: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Adam J. Morgan, I. Robert Silverman
  • Patent number: 8889737
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: November 18, 2014
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Morgan, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Patent number: 8889194
    Abstract: Disclosed is a compound and methods for use by an individual attempting to reduce or cease tobacco smoking or one exposed to environmental tobacco smoke. The compound includes a first component blocking nicotine receptor sites to reduce nicotine cravings or withdrawal symptoms, a second component increasing serotonin levels and acting synergistically with the first component to reduce nicotine cravings or withdrawal symptoms, assisting in maintaining body weight and reducing increased stress and anxiety, and a third component acting synergistically with the first and/or second component to reduce nicotine cravings or withdrawal symptoms, maintain body weight, and/or reduce increased stress and anxiety. The third component comprises a supplement that replenishes depleted body substance(s), repairs damaged body substance(s), and/or ameliorates the impaired function of body substance(s). Some combination of the first, second, and third component alters the perceived taste of tobacco smoke.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: November 18, 2014
    Inventor: Harlan Clayton Bieley
  • Publication number: 20140335080
    Abstract: Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3, R4, R5, J1, J2, X, Z, n1 and n2 are as defined herein, and wherein at least one of R1, R2 or R3 is an alkyl, alkenyl, aryl or aralkyl ester, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.
    Type: Application
    Filed: May 9, 2014
    Publication date: November 13, 2014
    Applicants: The University of British Columbia, British Columbia Cancer Agency Branch
    Inventors: Raymond J. Andersen, Marianne D. Sadar, Javier Garcia Fernandez, Nasrin R. Mawji, Jun Wang, Carmen Adriana Banuelos
  • Publication number: 20140336137
    Abstract: The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer.
    Type: Application
    Filed: July 28, 2014
    Publication date: November 13, 2014
    Inventors: Lisa Marie Frost, Stephen Martin Courtney, Frederick Arthur Brookfield, Vincent Jacob Kalish
  • Publication number: 20140328778
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis.
    Type: Application
    Filed: July 17, 2014
    Publication date: November 6, 2014
    Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Patent number: 8877809
    Abstract: Methods of retarding formation of a lipofuscin pigment in the retina and of treating or ameliorating the effects of a disease characterized by an accumulation of a lipofuscin pigment in a retina are provided. These methods include the step of administering to a patient in need thereof a substituted C20-retinoid in an amount sufficient to reduce accumulation of a lipofuscin pigment in the retina. Further provided are methods of retarding formation of A2E and/or ATR-dimer by replacing an all-frans-retinal (ATR) substrate with a C20-D3-retinal substrate under conditions sufficient to impede the formation of A2E. Compositions for retarding formation of a lipofuscin pigment in the retina containing a substituted C20-retinoid and a pharmaceutically acceptable carrier are also provided.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: November 4, 2014
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: Ilyas Washington
  • Publication number: 20140323572
    Abstract: An antimicrobial composition and method for extending the shelf-life of water, food/feed or food/feed ingredients, comprising: 5-25 wt. % nonanoic acid, 1-25 wt. % organic acid ester, 1-50 wt. % of a single or mixture of C1-C24 aldehydes, a mixture of C1-C24 organic acids, and water.
    Type: Application
    Filed: November 6, 2012
    Publication date: October 30, 2014
    Inventors: Julio Pimentel, Kurt Richardson
  • Patent number: 8865766
    Abstract: Provided herein, inter alia, are prodrugs of bimatoprost, methods of using the same and compositions including the same.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: October 21, 2014
    Assignee: Allergan, Inc.
    Inventors: David F. Woodward, Jenny W. Wang, Neil J. Poloso, Todd Gac, Robert M. Burk, Michael E. Garst
  • Patent number: 8859003
    Abstract: Hydrophobic liquids are microencapsulated by an enteric matrix in an environment substantially free of organic solvents. The process includes forming an emulsion of the enteric material and hydrophobic liquid in water, titrating the emulsion with an acid to form a particulate precipitate and optionally coating the particulate with a combination of enteric material and plasticizer.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: October 14, 2014
    Assignee: Intercontinental Great Brands LLC
    Inventors: Ahmad Akashe, Anilkumar Ganapati Gaonkar, Les Lawrence, Amado R. Lopez, George W. Haas, Dana Sebesta, Yan Wang
  • Patent number: 8859616
    Abstract: The present invention provides a method for stimulating hair growth in a mammalian species or converting vellus hair or intermediate hair to terminal hair or stimulating hair follicles to increase hair growth and one or more properties selected from the group consisting of luster, sheen, brilliance, gloss, glow, shine or patina of hair associated with the follicles or increasing one or more of: length, thickness, number, and density, of eyelash hair or eyebrow hair comprising applying to the skin of a patient a composition comprising an effective amount of an EP3 agonist or an EP4 agonist prodrug or a mixture thereof. Such compositions which are used in treating the skin or scalp of a human or non-human animal may comprise an effective amount of 3, 7 or 3 and 7 thia prostanoic acid. A mixture of 3,7-dithia PGE1 and 3,7-dithia PGE1-isopropyl ester is preferred for this treatment.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: October 14, 2014
    Assignee: Allergan, Inc.
    Inventors: Jenny W. Wang, David F. Woodward
  • Publication number: 20140303249
    Abstract: Anhydrous agents for topical application, comprising one or more C1-C4 alkyl esters of lactic acid, malic acid, tartaric acid or citric acid and physiologically acceptable excipients, are described for the treatment of nail disorders caused by mycoses and for nail care. The agents according to the invention are also suitable in veterinary medicine for treating fungal infections of the hooves, claws and talons of pets and farm animals and wild animals living in captivity.
    Type: Application
    Filed: June 11, 2014
    Publication date: October 9, 2014
    Inventor: Hans Meyer
  • Publication number: 20140303241
    Abstract: The present invention provides a series of derivatives of stilbenoid which are useful as new inhibitory agents against head and neck squamous cell carcinoma (HNSCC) and hepatoma.
    Type: Application
    Filed: March 28, 2014
    Publication date: October 9, 2014
    Applicant: AnnCare Bio-Tech Center Inc.
    Inventors: Sheng-Chu Kuo, Jai-Sing Yang, Min-Tsang Hsieh, Tian-Shung Wu, Kuo-Hsiung Lee, Huei-Wen Chen, Li-Jiau Huang, Hsin-Yi Hung, Tzong-Der Way, Ling-Chu Chang, Hui-Yi Lin, Yung-Yi Cheng, Chin-Yu Liu
  • Publication number: 20140296337
    Abstract: A method is provided for treating a subject in need of therapy for depression, anxiety, impaired cognition and/or pain comprising administering to said subject an amount of a ketogenic material sufficient to produce a ketosis in the subject sufficient to provide anti-depressant effect, cognition enhancing and/or analgesic effect. Preferred materials produce a ketosis is such that the total concentration of acetoacetate and (R)-3-hydroxybutyrate in the blood of the subject is raised to between 0.1 and 30 mM.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 2, 2014
    Inventors: David Greenwood, Wilfried Dimpfel
  • Publication number: 20140296241
    Abstract: The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain disorder (CRPS) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.
    Type: Application
    Filed: October 15, 2012
    Publication date: October 2, 2014
    Inventors: Irving W. Wainer, Ruin Moaddel, Michel Bernier, Carlos A. Zarate, Marc C. Torjman, Michael E. Goldberg, Mary J. Tanga
  • Publication number: 20140296183
    Abstract: A novel amine compound represented by the following formula (I), which is superior in immunosuppressive action, rejection suppressive action and the like, and shows reduced side effects such as bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or hydrates thereof, or solvate, as well as a pharmaceutical composition containing this compound and a pharmaceutically acceptable carrier. wherein R is a hydrogen atom or P(?O)(OH)2, X is an oxygen atom or a sulfur atom, Y is CH2CH2 or CH?CH, R1 is cyano or alkyl having a carbon number of 1 to 4 and substituted by a halogen atom(s), R2 is alkyl having a carbon number of 1 to 4 and optionally substituted by a hydroxyl group(s) or a halogen atom(s), R3 and R4 may be the same or different and each is a hydrogen atom or alkyl having a carbon number of 1 to 4, and n is 5-8.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 2, 2014
    Inventors: Masatoshi KIUCHI, Kaoru MARUKAWA, Nobutaka KOBAYASHI
  • Publication number: 20140288175
    Abstract: A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 25, 2014
    Applicant: Baylor Research Institute
    Inventor: Charles R. ROE
  • Patent number: 8841097
    Abstract: An edible oil obtained by culturing a microorganism belong to the genus Mortierella subgenus Mortierella in a medium containing a nitrogen source derived from soybean is discussed. The oils obtained have a low 24,25-methylenecholest-5-en-3?-ol content.
    Type: Grant
    Filed: April 21, 2006
    Date of Patent: September 23, 2014
    Assignee: Suntory Holdings Limited
    Inventors: Kenichi Higashiyama, Kengo Akimoto, Sakayu Shimizu
  • Patent number: 8835494
    Abstract: Pro-drugs of 1-(2-halo-biphenyl-4-yl)alkanecarboxylic acids are useful for preventing and/or treating neurodegenerative diseases, improving cognitive function and treating cognitive impairment.
    Type: Grant
    Filed: April 3, 2013
    Date of Patent: September 16, 2014
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Bruno Pietro Imbimbo, Luca Raveglia
  • Patent number: 8835508
    Abstract: A stable aqueous solution of sodium pyruvate for medical use, which contains 10-1,200 mM sodium pyruvate and a stabilizer of sodium pyruvate, wherein the said stabilizer is H+ which leads to pH 3.0-6.0 or NaCl which provides at least 20 mM Na+.
    Type: Grant
    Filed: April 17, 2009
    Date of Patent: September 16, 2014
    Inventor: Fangqiang Zhou
  • Publication number: 20140256808
    Abstract: This invention relates to the field of therapeutic agents for the treatment of Age-Associated Memory Impairment (AAMI). In particular, the present invention utilizes compositions comprising at least one compound capable of elevating ketone body concentrations in a mammal (e.g., ketogenic compounds), administered in an amount effective for treatment or prevention of loss of cognitive function caused by reduced neuronal metabolism in AAMI. In one embodiment, the composition includes medium chain triglycerides (MCT). In another embodiment, the compositions are administered in the presence of carbohydrate. The present invention also relates to oral dosage forms, in particular, a nutritional drink comprising at least one compound capable of elevating ketone body concentrations in a mammal.
    Type: Application
    Filed: May 5, 2014
    Publication date: September 11, 2014
    Applicant: Accera, Inc.
    Inventor: Samuel T. Henderson
  • Publication number: 20140248351
    Abstract: The present invention relates to a granulate and a pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof and stabilizer, in particular to a pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof and sucrose, polyethylene glycol, cyclodextrin, and combinations thereof and to a process for its preparation. The granulate and the pharmaceutical composition are particularly useful as a medicament, especially for the treatment of urinary incontinence. The present invention relates to use of sucrose, polyethylene glycol, cyclodextrin, and combinations thereof for stabilizing fesoterodine or a salt or a solvate thereof in a pharmaceutical composition.
    Type: Application
    Filed: April 10, 2012
    Publication date: September 4, 2014
    Applicant: LEK PHARMACEUTICALS D.D.
    Inventors: Sara Cesar, Klemen Naversnik, Tijana Stanic-Ljubin
  • Publication number: 20140242138
    Abstract: Method for the preparation of microencapsulated essential oils or a formulation thereof for various non-agricultural applications.
    Type: Application
    Filed: May 7, 2014
    Publication date: August 28, 2014
    Applicant: BOTANOCAP LTD.
    Inventors: Amnon Kritzman, Arie Markus, Pnina Strongin, Charles Linder
  • Patent number: 8815946
    Abstract: Provided herein are methods of preventing a fibrotic response and/or scarring in a wound, comprising administering to a subject a composition comprising an amount of an amide or ester of an alpha-ketoalkanoic acid effective to inhibit a proliferative and/or fibrotic response in the wound. In one instance, the wound is to a subject's cornea, such as a wound resulting from refractive surgery. In one embodiment, the amide or ester of an alpha-ketoalkanoic acid is ethyl pyruvate.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: August 26, 2014
    Assignee: University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Weixang Dai, James L. Funderburgh, Joel S. Schuman, Nirmala SundarRaj